TrialHaematologica2022

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.

Marcelo Capra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.